About

Bright Basin 94 presents Obsidian Thread, an independent resource on ibogaine episodes, screening, monitoring, recovery, legal restrictions, and safety. Our focus is to clarify uncertainty and help readers distinguish risk-managed access to an experimental intervention from claims of proven treatment efficacy.

Mission
Independence · Safety clarity · Evidence first
Audience
People considering ibogaine, their supporters, and clinicians seeking context

This site exists to gather, summarize, and point to primary sources about episodes and associated care pathways so readers can make informed choices. Our editorial focus is on how information is found, weighed, and presented rather than offering clinical recommendations.

We maintain a lightweight guide and cross-links to related materials; for example, some narrative and documentary resources are available through the ibogaine community, including the ibogaine documentary platform, which we reference when contextual narratives are relevant.

Our editorial approach

Bright Basin 94 curates material from registries, peer-reviewed literature, legal summaries, and official guidance. When we assert a factual point about practice or regulation we link to primary sources or authoritative summaries so readers can follow the chain of evidence themselves; for example, methods for vetting clinical research are commonly discussed in university resources such as the U.S. National Institutes of Health and explanatory overviews are accessible via broader references like evidence-based medicine.

What we cover

Content is organized into topical sections for screening, monitoring practices, recovery timelines, legal frameworks, and risk communication. For operational readers we provide links to contextual reporting and documentary material; we also connect readers to pages describing services and pathways where appropriate, such as the site's service overview at our services page.

How we source and vet information

We prioritize primary sources: peer-reviewed studies, clinical registries, regulatory notices, and official guidance from recognized institutions. Where policy or safety statements exist we link to the issuing body so readers can verify original text. Our aim is transparency in how material was selected and the limits of available evidence.

  • Independence
    No clinical referrals or commercial treatment endorsements.
  • Safety clarity
    Focus on measurable risks and mitigation, not promotion.
  • Evidence first
    Cite primary literature and official guidance where available.
  • Plain language
    Readable summaries with linked primary sources for deeper review.

Transparency and limits

We do not provide medical or legal advice. Where applicable we point to regulatory or clinical registries rather than offer prescriptive guidance; for example, readers seeking regulatory overviews can consult official health agency resources such as the U.S. Centers for Disease Control and Prevention for general principles about clinical safety and monitoring.

If you follow links to documentary material or community reporting, those sources will have their own standards and should be evaluated on their own terms. To explore narrative context curated by independent producers, see external documentary coverage including the ibogaine documentary platform we reference in context above.

Closing note

Bright Basin 94 aims to help people distinguish between experimental interventions and established treatments. Our editorial work is intentionally limited to aggregation, transparent sourcing, and plain-language context so readers can follow original evidence and reach informed decisions. For an overview of site content and pathways to topical pages, use the service index linked earlier or explore the site index at Bright Basin 94's front page.